{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:06:39Z","timestamp":1790766399733,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.thromres.2022.05.015","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:06:31Z","timestamp":1654545991000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms"],"prefix":"10.1016","volume":"216","author":[{"given":"Laura","family":"Herbreteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loula","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena\u00efg","family":"Le Clech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pan-Petesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Couturaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios","family":"Gerotziafas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lippert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.thromres.2022.05.015_bb0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.thromres.2022.05.015_bb0015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ajh.26008","article-title":"Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management","volume":"95","author":"Tefferi","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.thromres.2022.05.015_bb0020","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.23970","article-title":"Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis","volume":"90","author":"Barbui","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"26","key":"10.1016\/j.thromres.2022.05.015_bb0030","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2022.05.015_bb0035","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0040","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.23685","article-title":"Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients","volume":"89","author":"Montanaro","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"22","key":"10.1016\/j.thromres.2022.05.015_bb0045","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1182\/blood.V128.22.4257.4257","article-title":"Unusual site thrombosis: focus on myeloproliferative neoplasms with splanchnic or cerebral venous thrombosis","volume":"128","author":"Rupoli","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.thromres.2022.05.015_bb0050","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2022.05.015_bb0055","doi-asserted-by":"crossref","first-page":"17819","DOI":"10.1038\/s41598-021-97464-4","article-title":"Incidence, characteristics and risk factors of thromboembolic events in east asian patients with BCR-ABL1 negative myeloproliferative neoplasms","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.thromres.2022.05.015_bb0060","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.thromres.2022.05.015_bb0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia Vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.015_bb0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/bloodadvances.2020003628","article-title":"A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms","volume":"5","author":"Hamuly\u00e1k","year":"2021","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0040-1720979","article-title":"Hemorrhage in essential thrombocythemia or polycythemia Vera: epidemiology, location, risk factors, and lessons learned from the literature","volume":"121","author":"Nicol","year":"2021","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.015_bb0080","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.3390\/cancers12071746","article-title":"Essential thrombocythemia and acquired von willebrand syndrome: the shadowlands between thrombosis and bleeding","volume":"12","author":"Awada","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.thromres.2022.05.015_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-018-0101-8","article-title":"Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.015_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0225-5","article-title":"Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper","volume":"9","author":"Barbui","year":"2019","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0095","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1080\/00325481.2021.1880844","article-title":"Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants","volume":"133","author":"How","year":"2021","journal-title":"Postgrad. Med."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.015_bb0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.015_bb0110","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.thromres.2022.05.015_bb0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2022.05.015_bb0120","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.thromres.2022.05.015_bb0125","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.thromres.2022.05.015_bb0130","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.015_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-017-3164-x","article-title":"Incidence and impact of atrial arrhythmias on thrombotic events in MPNs","volume":"97","author":"Mah\u00e9","year":"2018","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.015_bb0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms","volume":"106","author":"Ianotto","year":"2017","journal-title":"Int. J. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2022.05.015_bb0145","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/bjh.16485","article-title":"Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK","volume":"189","author":"Curto-Garcia","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.015_bb0150","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-020-04350-6","article-title":"Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE\/VTE) in myeloproliferative neoplasms","volume":"100","author":"Huenerbein","year":"2021","journal-title":"Ann. Hematol."},{"issue":"10","key":"10.1016\/j.thromres.2022.05.015_bb0155","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.thromres.2022.05.015_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00566-5","article-title":"Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients","volume":"11","author":"How","year":"2021","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.thromres.2022.05.015_bb0165","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2022.05.015_bb0170","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Subcommittee on control of anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.015_bb0175","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2022.05.015_bb0180","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2022.05.015_bb0185","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s11239-021-02417-3","article-title":"The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Costa","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.thromres.2022.05.015_bb0190","first-page":"645","article-title":"Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study","volume":"114","author":"Weitz","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.015_bb0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.015_bb0200","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2022.05.015_bb0205","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2022.05.015_bb0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2017.180448","article-title":"Non-adherence to treatment with cytoreductive and\/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)","volume":"103","author":"Le Calloch","year":"2018","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.thromres.2022.05.015_bb0215","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2022.05.015_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12657","article-title":"Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment","volume":"6","author":"Barbui","year":"2022","journal-title":"Res Pract Thromb Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822002894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384822002894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:49:03Z","timestamp":1758736143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384822002894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":44,"alternative-id":["S0049384822002894"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2022.05.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2022.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}